TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07226349: A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 105 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$5,215,056

Rescue Site Savings

+$3,455,760

Unlock Full NCT07226349 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07226349 Rescue Dossier →